Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 28 September, 2017 by The TZ Newswire Staff

Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million

Sharpens Focus on Innovative ADAPTIR

®

Bispecific Antibody Platform

and IXINITY

®

Commercial Asset

See also
- Next Article ECB’s Praet says French President’s Macron reform are very encouraging
- Previous Article Inflation data coming from Japan today – preview
Editorial Calender

September 2017

M T W T F S S

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30

« Aug Oct »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar